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Background: The Chimney graft (CG) procedure is one of the novel modification techniques of the endovascular
aneurysm repair (EVAR) surgery to treat suprarenal and juxtarenal abdominal aortic aneurysms. Other indications for
the use of CG placement include thoracic and thoracoabdominal aneurysms with supraortic branches orifice
involvement and cases of common iliac artery aneurysms with or without internal iliac artery involvement. The
technique is used in patients who due to aortic-neck morphology and lack of adequate fixation and/or sealing
zones are not eligible for standard EVAR. In this procedure, a parallel stent-graft is placed adjacent to the main
body of the aortic endograft to maintain blood supply to renovisceral or supraortic branches, once the body of the
aortic stent-graft is deployed. Symptomatic occlusions of the CG with novel renovascular hypertension were not
described until now.
Case presentation: A-64-year-old male patient, presented with new-onset malignant hypertension, 13 months
after an EVAR operation with CG placement to the left renal artery. The patient was on preventive clopidrogel
therapy, which was withheld temporarily for several days, one month before presentation. Imaging studies revealed
a novel form of iatrogenic renovascular hypertension, caused by occlusion of the CG. Any attempt to recanalize the
covered stent or revascularize the left kidney was rejected and conservative treatment was chosen. Seven months
after presentation, blood pressure was within normal ranges with little need for antihypertensive therapy.
Conclusions: Physicians should be aware that the novel emerging techniques of EVAR to overcome the
limitations of the aortic-neck anatomy may still adversely influence the renal outcome with potential development
of new-onset hypertension.
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Endovascular aneurysm repair (EVAR) has gained wide-
spread acceptance as the procedure of choice for repair
of infrarenal abdominal aortic aneurysms (AAA) in patients
with suitable aortic anatomy [1]. The improvement of the
technique and surgeon’s skills has extended the possible
indication for repair to patients with a more complex
aortic anatomy [1,2]. Despite these improvements, the* Correspondence: gilc@tasmc.health.gov.il
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reproduction in any medium, provided the ormain anatomic limitation to EVAR is the proximal aortic-
neck anatomy. There is no consensus about the method of
choice to repair suprarenal or juxtarenal AAAs [2]. Open
repair is an effective method, yet the post-operative risks
and the high morbidity and mortality rates make this
operation suitable to low-risk patients [3]. The standard
EVAR procedure for infrarenal AAAs cannot be applied
to suprarenal or juxtarenal AAAs since it is accompanied
by high rate of adverse events including proximal endoleak,
migration and mainly aortic side branches occlusion with
possible renovisceral ischemia [1,2,4]. Novel modifications
of the traditional EVAR procedure have evolved in order
to offer less invasive approach to repair suprarenal or
juxtarenal AAA. The fenestrated and branched EVARLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tive to open repair or standard EVAR techniques that
would not compromise blood perfusion to the aortic
side branches, since the sealing and/or fixation zone is
translocated proximal or distal away from the target
vessels [4,5]. However, the endovascular stent grafts that
are used in the fenestrated and branched EVAR are
custom-made and require measuring, fitting and a period
of time for graft preparation and supply. Therefore, these
two costly techniques are only suitable for elective repair
of AAA and not in emergent cases [1,2,4,5]. In 2003,
Greenberg et al, have introduced the novel chimney graft
(CG) procedure (a.k.a. the “snorkel technique”) in order
to overcome some of the limitations of the fenestrated
and branched EVAR [6]. The CG technique involves
placing of parallel stent grafts adjacent to the main
body of the aortic endograft to maintain blood supply
to renal and other visceral branches post- aneurysm
exclusion. Contrary to EVAR with the fenestrated or
branched technique, the CG technique involves standard
off-the-shelf stent grafts and can be used in emergent
cases [1,2]. Possible indications for the use of CGs, other
than treating suprarenal and juxtarenal abdominal aortic
aneurysms, include thoracic and thoracoabdominal aneu-
rysms with supraortic branches orifice involvement and
suitable cases of common iliac artery aneurysms with or
without internal iliac artery involvement [7,8]. A potential
major drawback of the EVAR procedures is the presence
of endoleaks (i.e. persistent flow of blood into the
aneurysm sac after device placement). Endoleaks were
reported to complicate up to 25% of EVAR operations
with CG placement. However, endoleak repair not ne-
cessary in most cases [1].
Hereby we present a novel etiology of malignant renovas-
cular hypertension caused by a renal artery CG occlusion.
Case presentation
A 64-year-old male patient was admitted to the emergency
ward for severe occipital headache, visual disturbances
and new-onset severe hypertension. The symptoms were
initially noted three days before admission. His medical
history was notable for hypercholesterolemia with ator-
vastatin therapy. Thirteen months before admission, an
EVAR operation was performed to repair a rapidly
expanding AAA with a diameter of 53 mm. EVAR with
Endurant endograft (Medtronic, Minneapolis, MN) was
combined with a Chimney procedure into the left renal
artery, using a balloon expandable covered stent-graft
(7 × 38 mm Advanta V12; Atrium Medical Corp). The
Chimney technique was used due to irregular aortic neck
with posterior ulceration and high difference of right renal
artery origin, 10 mm above the left renal artery origin.
Antiplatelet therapy with clopidrogel (75 mg/day) was
initiated after the surgery. During the 6th month follow-upan abdominal computed-tomography angiography (CTA)
revealed a well functioning aortic stent and a patent CG
(Figure 1A-B). One month before presentation with hyper-
tension, clopidrogel therapy was temporarily stopped for
six days, in order to undergo an elective laparoscopic bilat-
eral inguinal hernia repair (IHR) surgery. The immediate-
post operative follow-up after the IHR was uneventful with
normal blood pressure measuring.
At admission, the patient was without abdominal or
flank pain. Blood pressure was 224/113 mmHg, heart
rate 91 beats per minute. Ophthalmology examination
including optical coherence tomography (OCT) revealed
retinal detachment and a large accumulation of subretinal
fluid in the right eye. There were no murmurs or bruits
over the renal arteries. Laboratory results at admission
with comparison to values taken five weeks before admis-
sion are summarized in Table 1.
Renal duplex ultrasound failed to detect blood flow
into the left renal artery. CTA demonstrated an abdom-
inal endograft that was patent without a leak, dissection
or migration. However, a total occlusion of the CG to
the left renal artery was noted without stent kinking
(Figure 1C-D). The left renal parenchyma was smaller
compared to the previous CTA, with decreased contrast
media uptake and hypodense wedge areas, indicative
of multiple infract (Figure 1E).
Medical therapy to reduce blood pressure was initiated
with intravenous nitroglycerine and subsequently with
maximal dosage of oral ramipril, amlodipine and hydro-
chlorothiazide. Blood pressure was lowered gradually
and the patient was discharged with improvement of
ophthalmological findings and serum creatinine levels of
1.5 mg/dL. Eight months after discharge, the patient was
asymptomatic with only ramipril 2.5 mg/day as antihy-
pertensive medication. At that point of time, office blood
pressure was measured 128/81 mmHg and serum cre-
atinine levels were of 1.3 mg/dL. The protein excretion
in urine was of 280 mg/day.
Conclusions
The newer techniques of EVAR, such as the fenestrated,
branched or CG techniques, can pose an increased risk
of renal injury because of several mechanisms, including
higher doses of nephrotoxic contrast media and instru-
mentation of the renal arteries, which can lead to emboli
and inadequate revascularization. Other potential causes
renal injury are mechanical stenoses or kinking and in-
stent restenoses due to neo intimal hyperplasia [5,9].
Indeed, occlusion of renal arteries and decline of esti-
mated glomerular filtration rate (eGFR) were reported
with the fenestrated and branched techniques [9]. Several
reports have addressed the short and mid-term outcome
of EVAR with the use of the CG technique including the
renal outcome [10-13]. It is important to remember that
Figure 1 Abdominal CT-angiography (CTA) of a 64-year old patient after EVAR with placement of GC into the left renal artery. A-B.
Five months before presentation, during routine post-operative follow up and C-E. At presentation with malignant renovascular hypertension;
A. Curved Multi Planar Reconstruction (cMPR) image showing a patent CG (arrow). B. A volume rendering image showing patent aortic stent-graft and
patent CG (arrow) with symmetric enhancement of the two kidneys. C. cMPR image showing occluded CG with near complete occlusion of the left
renal artery. A trickle of contrast is demonstrated in a distal segment of the artery. D. A volume rendering image showing the occluded CG with lack of
enhancement of the left kidney. E. Axial image showing the occluded CG (short arrow) and small, shrunken non enhancing left kidney (long arrow).
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time considered in cases with the need of CG into the
superior mesenteric artery because of the risk that placing
more than two CGs might compromise the proximal seal
[11]. A recent review by Moulkakis et al. summarized the
results of 15 studies with the placement of a total 134 CGs
and a mean follow-up of nine months. The patency-rate of
CG was 97.8% (131/134) with one patient reported to have
renal GC occlusion after 45 days, necessitating urgentthrombectomy and bypass [10]. Another report of 28
patients after EVAR with placement of 56 CGs, found
one case of renal CG occlusion after 90 days (98.2%
GCs patency). The occlusion was asymptomatic and
without deterioration of kidney function [12]. Other
adverse renal effects that were described with the CG
technique include: dissection of the stented renal artery
[13], perinephric hematoma [1], and acute kidney in-
jury (AKI) with the need for renal replacement therapy
Table 1 Laboratory results at admission and five weeks
before admission
Parameters At admission Five weeks
before
admission
Serum creatinine (mg/dl) 1.5 1.2
Potassium (meq/L) 3.8 4.2
Sodium (meq/L) 138 140
Lactate dehydrogenase (U/L) 436 288
Alkaline phosphatase (U/L) 114 79
Bicarbonate meq/L 24 -
Hemoglobin g/dl 12.1 10.1
WBC, (x103/μl) 8.7 7.1
Platelets (x109/L) 180000 152000
Plasma renin activity (PRA) in
the supine position (ng/ml/hr)
>37 -
Urinalysis Without hematuria or
leukocyturia
-
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outcome in 21 patients treated with EVAR and CG
technique versus 21 anatomically-matched patients that
underwent an open repair surgery found similar decline of
eGFR in both groups. Overall, six patients (29%) of the
21 patients treated with EVAR and CG had AKI [11].
To the best of our knowledge, this is the first detailed
description of a late occurrence (more than a year post
CG placement) of thrombosis to the CG with the presenta-
tion of severe renovascular hypertension. The pathophysi-
ology of renovascular hypertension, involves increased
activation of the renin-angiotensin axis. Therefore, med-
ical treatment was initiated and maintained with the
angiotensin converting enzyme inhibitor, ramipril [14].
Any attempt to recanalize the covered stent or
revascularize the left kidney was rejected. The rational for
our conservative approach was that the symptoms of
malignant hypertension persisted for several days before
presentation and that the left kidney was found to be
small. We believe that revascularization of occluded renal
artery CG, should be considered in acute events without
signs of prolonged ischemia to the affected kidney [15].
Different invasive approaches of revascularization are
possible, such as percutaneous endovascular therapy or
distal bypass. There is lack of sufficient data to indicate
which method of revascularization is preferable.
In the case described here, clopidrogel therapy was
stopped for several days, one month prior to presentation.
It is possible that the temporary perioperative cessation of
antiplatelet therapy has initiated, or at least exacerbated, a
thrombotic occlusion process inside the CG. The lack of
flank pain, the slight elevation of lactate dehydrogenase
from baseline measures and the normal urinalysis, may
suggest that the thrombosis in the CG was not merely
an acute event, just shortly before the appearance ofsymptoms. There is lack of evidence-based guidelines
about the appropriate perioperative antiplatelet therapy
for CGs, as well as other stents, after more than a year
from stent placement. A balance between the risk of stent
thrombosis and the risk of bleeding is hard to find in
clinical practice [16]. Our case demonstrates that late-
thrombosis, more than a year after placement of a CG, is
a potential threat. One needs to consider the merits versus
the risks of withholding antiplatelet therapy in patients
after EVAR with CG, even as a temporary measure before
invasive procedures. We believe that a reasonable
approach before elective operations for patients with
EVAR and CG, is to stop antiplatelet therapy, one week
prior to elective surgery and to temporarily initiate
anticoagulation treatment (e.g. subcutaneous Enoxaparin).
Anticoagulation will be stopped, one day before the
procedure, and antiplatelet therapy will be re-initiated in
the second post-operative day.
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